Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

New Keys to Immunosuppression

Vaccines and Inflammatory Bowel Disease

Kotton C.N.

Author affiliations

Transplant Infectious Disease and Compromised Host Program, Division of Infectious Diseases, Massachusetts General Hospital, and Department of Medicine, Harvard Medical School, Boston, Mass., USA

Related Articles for ""

Dig Dis 2010;28:525–535

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of New Keys to Immunosuppression

Published online: September 30, 2010
Issue release date: October 2010

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI

Abstract

Patients with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, are at increased risk for infection due to both their underlying disease and the immunosuppressive therapy used to treat the disease. Numerous groups and papers support the routine vaccination of IBD patients, yet many opportunities to vaccinate this vulnerable population are missed. While immunogenicity may be somewhat attenuated, some protection is likely to be provided, especially when vaccination is performed during periods of reduced immunosuppression. Live viral vaccines should be avoided during periods of more intense immunosuppression; further specific guidance on this as well as information on individual vaccines is provided.

© 2010 S. Karger AG, Basel


References

  1. Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, Orenstein W: Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:677–692.
  2. Esteve Comas M, Loras Alastruey C, Fernandez-Banares F: How do we manage vaccinations in patients with inflammatory bowel disease? Dig Dis 2009;27:370–374.
  3. Viget N, Vernier-Massouille G, Salmon- Ceron D, Yazdanpanah Y, Colombel JF: Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008;57:549–558.
  4. Culver EL, Travis SP: How to manage the infectious risk under anti-TNF in inflammatory bowel disease. Curr Drug Targets 2010;11:198–218.
  5. Wasan SK, Baker SE, Skolnik PR, Farraye FA: A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010;105:1231–1238.
  6. Lu Y, Jacobson D, Bousvaros A: Immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1417–1423.
  7. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D’Haens G, Domènech E: European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47–91.
    External Resources
  8. Gupta A, Macrae FA, Gibson PR: Vaccination and screening for infections in patients with inflammatory bowel disease: A survey of Australian gastroenterologists. Intern Med J 2009, E-pub ahead of print.
  9. Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Frenck RW, Targan SR, Vasiliauskas EA: Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101:1834–1840.
  10. Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L: Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in northeast France. Inflamm Bowel Dis 2010;16:916–924.
  11. Muller AF, Cornford E, Toghill PJ: Splenic function in inflammatory bowel disease: assessment by differential interference microscopy and splenic ultrasound. Q J Med 1993;86:333–340.
  12. Di Sabatino A, Carsetti R, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Tinozzi FP, Tinozzi S, Corazza GR: Immunoglobulin M memory B cell decrease in inflammatory bowel disease. Eur Rev Med Pharmacol Sci 2004;8:199–203.
  13. Di Sabatino A, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Corazza GR, Carsetti R: Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease. Am J Gastroenterol 2005;100:1788–1795.
  14. Corazzo GR, Gasbarrini G: Defective splenic function and its relation to bowel disease. Clin Gastroenterol 1983;12:651–669.
  15. Muller AF, Toghill PJ: Hyposplenism in gastrointestinal disease. Gut 1995;36:165–167.
  16. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA: High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309–313.
  17. Schattner A: Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005;23:3876–3886.
  18. Nielsen HJ, Mortensen T, Holten-Andersen M, Brunner N, Sorensen S, Rask-Madsen J: Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol 2001;36:265–269.
  19. Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN: Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology 2009;136:451–458.
  20. van der Hoeven JG, de Koning J, Masclee AM, Meinders AE: Fatal pneumococcal septic shock in a patient with ulcerative colitis. Clin Infect Dis 1996;22:860–861.
  21. Foster KJ, Devitt N, Gallagher PJ, Abbott RM: Overwhelming pneumococcal septicaemia in a patient with ulcerative colitis and splenic atrophy. Gut 1982;23:630–632.
  22. Garcia-Vidal C, Rodriguez-Fernandez S, Teijon S, Esteve M, Rodriguez-Carballeira M, Lacasa JM, Salvador G, Garau J: Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009;28:331–337.
  23. Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, Simpson P, Barolet-Garcia C, Ward J, Targan SR, Vasiliauskas EA: Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:148–154.
  24. Centers for disease control and prevention: recommended adult immunization schedule: United States, 2010. Morbidity and Mortality Weekly Report. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm5901a5.htm (accessed July 14, 2010).
  25. Rahier JF, Yazdanpanah Y, Viget N, Travis S, Colombel JF: Review article: Influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010;31:5–10.
  26. Shale MJ: The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull 2009;92:61–77.
  27. Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L: From the medical board of the national psoriasis foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008;58:94–105.
  28. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD: British association of dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987–1019.
  29. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O’Dell J, Turkiewicz AM, Furst DE: American college of rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762–784.
  30. Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, Gregas MC, Burchett SK, Bousvaros A: Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009;104:444–453.
  31. Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN: Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:851–856.
  32. Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP: The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008;67:713–716.
  33. Stevens R, Oliver M, Brogan M, Heiserodt J, Targan S: Defective generation of tetanus-specific antibody-producing b cells after in vivo immunization of Crohn’s disease and ulcerative colitis patients. Gastroenterology 1985;88:1860–1866.
  34. Marin M, Guris D, Chaves SS, Schmid S, Seward JF: Prevention of varicella: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2007;56:1–40.
    External Resources
  35. Springfeld C, Sauerbrei A, Filusch A, Konstandin M, Hartschuh W, Sauer P, Encke J, Stremmel W, Schnitzler P: Fatal varicella in an immunocompromised adult associated with a European genotype E2 variant of varicella zoster virus. J Clin Virol 2009;44:70–73.
  36. Balato N, Gaudiello F, Balato A, Ayala F: Development of primary varicella infection during infliximab treatment for psoriasis. J Am Acad Dermatol 2009;60:709–710.
  37. Leung VS, Nguyen MT, Bush TM: Disseminated primary varicella after initiation of infliximab for Crohn’s disease. Am J Gastroenterol 2004;99:2503–2504.
  38. Vonkeman H, ten Napel C, Rasker H, van de Laar M: Disseminated primary varicella infection during infliximab treatment. J Rheumatol 2004;31:2517–2518.
  39. Harpaz R, Ortega-Sanchez IR, Seward JF: Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2008;57:1–30; quiz CE32–34.
    External Resources
  40. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Jr., Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–2284.
  41. Kotton CN: Nailing down the shingles in IBD. Inflamm Bowel Dis 2007;13:1178–1179.
  42. Gupta G, Lautenbach E, Lewis JD: Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:1483–1490.
  43. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ: Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol 2009;104:2524–2533.
  44. Domm S, Cinatl J, Mrowietz U: The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008;159:1217–1228.
  45. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P: Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501–508.
  46. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A: Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737–744.
  47. Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, Min YI, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune J, Ytterberg SR, Allen NB, Stone JH: Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med 2005;118:1416.
  48. Whitley RJ, Gnann JW Jr: Herpes zoster in the age of focused immunosuppressive therapy. JAMA 2009;301:774–775.
  49. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, Arvin AM: Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002;347:26–34.
  50. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM: Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004;53:1363–1365.
  51. Vida Perez L, Gomez Camacho F, Garcia Sanchez V, Iglesias Flores EM, Castillo Molina L, Cerezo Ruiz A, Casais Juanena L, De Dios Vega JF: Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc) 2009;132:331–335. (Article in Spanish.)
  52. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ: Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 1995;345:1071–1074.
  53. Seagroatt V: MMR vaccine and Crohn’s disease: Ecological study of hospital admissions in England, 1991 to 2002. BMJ 2005;330:1120–1121.
  54. D’Souza Y, Dionne S, Seidman EG, Bitton A, Ward BJ: No evidence of persisting measles virus in the intestinal tissues of patients with inflammatory bowel disease. Gut 2007;56:886–888.
  55. Davis RL, Kramarz P, Bohlke K, Benson P, Thompson RS, Mullooly J, Black S, Shinefield H, Lewis E, Ward J, Marcy SM, Eriksen E, Destefano F, Chen R: Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the vaccine safety datalink project. Arch Pediatr Adolesc Med 2001;155:354–359.
  56. Bernstein CN, Rawsthorne P, Blanchard JF: Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. Inflamm Bowel Dis 2007;13:759–762.
  57. Updated recommendation from the advisory committee on immunization practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep 2009;58:1042–1043.
    External Resources
  58. Kane S, Khatibi B, Reddy D: Higher incidence of abnormal pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008;103:631–636.
  59. Schoepfer AM, Flogerzi B, Fallegger S, Schaffer T, Mueller S, Nicod L, Seibold F: Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008;103:2799–2806.
  60. Kotton CN, Hibberd PL: Travel medicine and the solid organ transplant recipient. Am J Transplant 2009;9:S273–S281.

Article / Publication Details

First-Page Preview
Abstract of New Keys to Immunosuppression

Published online: September 30, 2010
Issue release date: October 2010

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.